Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice

Table 1 Summary of recently published findings on bexarotene in mouse models of Aβ amyloidosis related to the study presented here (first row)

Model	Age (months)	Days of treatment	Brain insoluble/plaque Aβ	Brain soluble Aβ	Fear conditioning
APP_swe/PS1_∆E9	8 and 11	3, 7 and 14,	No effect	N/A	No effect
APP/PS1 + APOE3/4 [14]	7	15	No effect	No effect	N/A
APP _swe/PS1_∆E9[15]	7	11	No effect	No effect	N/A
APP _swe/PS1_∆E9[16]	10	14	No effect	No effect	N/A
APP_swe/PS1_∆E9[17]	6	7	No effect	No effect	N/A
5XFAD[17]	3-4	7	No effect	Decrease Aβ40 only	N/A
APP/PS1-21[17]	9	26	No effect	No effect	N/A

N/A indicates that the listed data point was not reported. Superscript numbers indicate reference number of the original work.

ISSN: 1750-1326